| Assessment Status | Rapid Review Complete |
| HTA ID | 26028b |
| Drug | Brentuximab vedotin in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) |
| Brand | Adcetris® |
| Indication | Brentuximab vedotin (Adcetris®) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma. |
| Assessment Process | |
| Rapid review commissioned | 10/06/2026 |
| Rapid review completed | 22/07/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of BrECADD for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here